

Breast Cancer[®]

U P D A T E

An Audio Review Journal for Nurses

Management of Breast Cancer in the Adjuvant and Metastatic Settings

EDITOR

Neil Love, MD

INTERVIEWS

Maureen Major Campos, RN, MS

Charles L Vogel, MD

Allan Lipton, MD

*Additional comments by
three women with breast cancer*



A Continuing Nursing Education Audio Series

OVERVIEW OF ACTIVITY

Breast cancer is one of the most rapidly evolving fields in oncology nursing. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, oncology nurses must be well informed of these advances, the efficacy of new agents and regimens and strategies to minimize and manage associated toxicities. This program provides nurses with access to the latest research developments in systemic therapy and the opinions of oncology nurses and clinical investigators with experience and expertise in the field, in addition to perspectives of patients undergoing treatment.

PURPOSE STATEMENT

To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer.

EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *BREAST CANCER UPDATE FOR NURSES*

- Counsel patients with hormone receptor-positive breast cancer about the benefits and risks of endocrine therapy.
- Compare and contrast the efficacy, safety and tolerability of chemotherapeutic regimens used in the adjuvant and metastatic treatment of breast cancer.
- Communicate the pivotal role of targeted biologic therapy for the treatment of early and advanced HER2-positive breast cancer to appropriate patients.
- Demonstrate knowledge of the evidence-based use of bevacizumab in the treatment of metastatic breast cancer, and describe the rationale for its ongoing investigation in the adjuvant setting.
- Implement patient supportive care and educational strategies to minimize toxicities associated with the systemic treatment of breast cancer.
- Integrate validated genomic assays into the clinical management of early breast cancer.
- Recall the clinical indications for initiating bisphosphonate therapy for patients with metastatic breast cancer, and identify the signs of treatment-related osteonecrosis of the jaw.
- Recognize the psychosocial and emotional needs of patients, caregivers and their loved ones facing the diagnosis and treatment of breast cancer.

ACCREDITATION STATEMENTS

This educational activity for 2.75 contact hours is provided by Research To Practice during the period of December 2008 through December 2009.

Research To Practice is an approved provider of continuing nursing education by the New Jersey State Nurses Association, Provider Number P215-01/07-10. NJSNA is accredited by the ANCC Commission on Accreditation. Provider Approval is valid through January 31, 2010.

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE program. This book contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website ResearchToPractice.com/BCU/Nurses also includes links to relevant abstracts and full-text articles.

The Post-test and Educational Assessment and Credit Form may be completed in this book and either mailed to Research To Practice, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131 or faxed to (800) 447-4310. They may also be completed online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.

If you would like to discontinue your complimentary subscription to *Breast Cancer Update for Nurses*, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

Breast Cancer®

U P D A T E

EDITOR




Neil Love, MD
Medical Oncologist
Editor
Breast Cancer Update for Nurses
Research To Practice
Miami, Florida



Charles L. Vogel, MD
Senior Research Advisor for
Breast Cancer, Aptium Oncology
Lynn Regional Cancer Center
West Campus, Boca Raton
Community Hospital
Scientific Advisor
Cancer Research Network Inc
Boca Raton, Florida



**Maureen Major Campos,
RN, MS**
Clinical Nurse Specialist
Evelyn H Lauder Breast Center
Memorial Sloan-Kettering
Cancer Center
New York, New York



Allan Lipton, MD
Professor of Medicine and Oncology
Division of Hematology/Oncology
MS Hershey Medical Center
The Pennsylvania State University
Hershey, Pennsylvania

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ms Major Campos — Consulting Agreements: Eisai Inc, Genentech BioOncology; **Speakers Bureau:** Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, **Dr Vogel** — Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Sanofi-Aventis; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genzyme Corporation, GlaxoSmithKline, Pfizer Inc, Sanofi-Aventis; Paid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, Pfizer Inc, Sanofi-Aventis; **Speakers Bureau:** Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Sanofi-Aventis. **Dr Lipton** — Consulting Fees: Amgen Inc, GlaxoSmithKline, Merck and Company Inc, Novartis Pharmaceuticals Corporation; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation.

EDITOR — **Dr Love** does not receive any direct remuneration from industry. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Breast Cancer Update for Nurses — Issue 2, 2008**QUESTIONS (PLEASE CIRCLE ANSWER):**

- Side effects of bevacizumab include all of the following except _____.**
 - Alopecia totalis
 - Epistaxis
 - Hypertension
 - Proteinuria
- Which of the following is a benefit of nanoparticle albumin-bound (nab) paclitaxel?**
 - Absence of peripheral neuropathy
 - Avoidance of premedications
 - Oral administration
- Arthralgias are more commonly associated with which agent or class of agents in endocrine therapy?**
 - Aromatase inhibitors
 - Fulvestrant
 - Tamoxifen
- Determining a patient's baseline bone density is recommended prior to the initiation of _____ therapy.**
 - Anti-HER2
 - Anthracycline
 - Aromatase inhibitor
 - Taxane
- The Oncotype DX® genomic assay is useful in determining whether adjuvant chemotherapy would be beneficial for patients with early, estrogen receptor-_____ breast cancer.**
 - Negative
 - Positive
- In the RIBBON 1 trial, patients with untreated metastatic breast cancer are randomly assigned to receive chemotherapy with or without _____.**
 - Bevacizumab
 - Lapatinib
 - Trastuzumab
- Which of the following bisphosphonates are FDA approved for the treatment of cancer metastases to bone?**
 - Clodronate
 - Ibandronate
 - Pamidronate
 - Zoledronic acid
 - Both c and d
- Current guidelines recommend that prior to the initiation of _____, patients should undergo a dental examination.**
 - Bevacizumab
 - Lapatinib
 - Trastuzumab
 - Zoledronic acid
- In postmenopausal patients with hormone-responsive breast cancer, which of the following endocrine therapies may be used in a sequential fashion?**
 - Anastrozole
 - Fulvestrant
 - Tamoxifen
 - All of the above
- Clinical trials have reported that adjuvant trastuzumab administered to a patient with HER2-positive breast cancer reduces her risk of recurrence by approximately _____.**
 - 10 percent
 - 20 percent
 - 30 percent
 - 50 percent

Breast Cancer Update for Nurses — Issue 2, 2008

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART ONE — Please tell us about your experience with this educational activity

BEFORE completion of this activity, how would you characterize your level of knowledge on the following topics?

4 = Very good 3 = Above average 2 = Adequate 1 = Suboptimal

Potential risks associated with bisphosphonate therapy	4	3	2	1
Nursing management of side effects secondary to endocrine therapies	4	3	2	1
Use of <i>OncoType</i> DX in adjuvant treatment decisions	4	3	2	1
Safety and efficacy of bevacizumab in the metastatic setting.....	4	3	2	1

AFTER completion of this activity, how would you characterize your level of knowledge on the following topics?

4 = Very good 3 = Above average 2 = Adequate 1 = Suboptimal

Potential risks associated with bisphosphonate therapy	4	3	2	1
Nursing management of side effects secondary to endocrine therapies	4	3	2	1
Use of <i>OncoType</i> DX in adjuvant treatment decisions	4	3	2	1
Safety and efficacy of bevacizumab in the metastatic setting.....	4	3	2	1

Was the activity evidence based, fair, balanced and free from commercial bias?

Yes No

If no, please explain:

Will this activity help you improve patient care?

Yes No Not applicable

If no, please explain:

Did the activity meet your educational needs and expectations?

Yes No

If no, please explain:

Please respond to the following LEARNER statements by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = Learning objective not met N/A = Not applicable

As a result of this activity, I will be able to:

- Counsel patients with hormone receptor-positive breast cancer about the benefits and risks of endocrine therapy.....4 3 2 1 N/M N/A
- Compare and contrast the efficacy, safety and tolerability of chemotherapeutic regimens used in the adjuvant and metastatic treatment of breast cancer.....4 3 2 1 N/M N/A
- Communicate the pivotal role of targeted biologic therapy for the treatment of early and advanced HER2-positive breast cancer to appropriate patients.4 3 2 1 N/M N/A
- Demonstrate knowledge of the evidence-based use of bevacizumab in the treatment of metastatic breast cancer, and describe the rationale for its ongoing investigation in the adjuvant setting.....4 3 2 1 N/M N/A
- Implement patient supportive care and educational strategies to minimize toxicities associated with the systemic treatment of breast cancer.4 3 2 1 N/M N/A
- Integrate validated genomic assays into the clinical management of early breast cancer.....4 3 2 1 N/M N/A
- Recall the clinical indications for initiating bisphosphonate therapy for patients with metastatic breast cancer, and identify the signs of treatment-related osteonecrosis of the jaw.4 3 2 1 N/M N/A
- Recognize the psychosocial and emotional needs of patients, caregivers and their loved ones facing the diagnosis and treatment of breast cancer.....4 3 2 1 N/M N/A

What other practice changes will you make or consider making as a result of this activity?

.....

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

What additional information or training do you need on the activity topics or other oncology-related topics?

.....

Additional comments about this activity:

.....

.....

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

- Yes, I am willing to participate in a follow-up survey.
- No, I am not willing to participate in a follow-up survey.

PART TWO — Please tell us about the editor and faculty for this educational activity

4 = Very good 3 = Above average 2 = Adequate 1 = Suboptimal

Faculty	Knowledge of subject matter				Effectiveness as an educator			
Maureen Major Campos, RN, MS	4	3	2	1	4	3	2	1
Charles L Vogel, MD	4	3	2	1	4	3	2	1
Allan Lipton, MD	4	3	2	1	4	3	2	1
Editor	Knowledge of subject matter				Effectiveness as an educator			
Neil Love, MD	4	3	2	1	4	3	2	1

Please recommend additional faculty for future activities:

.....

Other comments about the editor and faculty for this activity:

.....

REQUEST FOR CREDIT — Please print clearly

Name:..... Specialty:.....

Credentials:

MD DO PharmD NP CNS RN PA Other:.....

Professional License Number:..... Last 4 Digits of SSN (required):.....

Street Address:..... Box/Suite:.....

City, State, Zip:.....

Telephone:..... Fax:.....

Email:.....

Signature:..... Date:.....

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/BCU/Nurses.

Breast Cancer®

U P D A T E

Editor	Neil Love, MD
Managing Editor	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Senior Director, Medical Affairs	Aviva Asnis-Alibozek, PA-C, MPAS
Writers	Lillian Sklaver Poltorack, PharmD Douglas Paley
Continuing Education Administrator for Nursing	Sally Bogert, RNC, WHCNP
Content Validation	Margaret Peng Erin Wall Clayton Campbell Jessica McCarrick
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Graphic Designers	Jessica Benitez Jason Cunnius Tamara Dabney Shantia Daniel Claudia Munoz
Senior Production Editor	Alexis Oneca
Traffic Manager	Tere Sosa
Copy Editors	Dave Amber Margo Harris David Hill Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone
Production Manager	Tracy Potter
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Faculty Relations Manager	Melissa Vives
CME Director/CPD Director	Isabelle Tate
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com Email: CE@ResearchToPractice.com
For CME/CNE Information	

Copyright © 2008 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Breast Cancer[®]

U P D A T E

Copyright © 2008 Research To Practice.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.

Research To Practice[®]

Sponsored by Research To Practice.

Last review date: December 2008

Release date: December 2008

Expiration date: December 2009

Contact hours: 2.75